These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 16780279)

  • 21. Biological treatments for systemic lupus erythematosus.
    Isenberg D; Leckie MJ
    Scand J Rheumatol; 2002; 31(4):187-91. PubMed ID: 12369648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B cells in SLE: different biological drugs for different pathogenic mechanisms.
    Diamanti AP; Rosado MM; Carsetti R; Valesini G
    Autoimmun Rev; 2007 Dec; 7(2):143-8. PubMed ID: 18035325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Solubility of immune complexes and activity of the alternative complement pathway in patients with systemic lupus erythematosus].
    Riera Cervantes N; Geffner J; Isturiz MA; Manni JA; de Bracco MM
    Rev Clin Esp; 1985 Oct; 177(6):254-7. PubMed ID: 4081196
    [No Abstract]   [Full Text] [Related]  

  • 24. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Studies of antilymphocyte antibodies in sera of patients with systemic lupus erythematosus. Analysis of antibodies to activated T cells].
    Sano H; Kumagai S; Imura H; Uchiyama J; Yodoi J; Maeda M
    Arerugi; 1986 Feb; 35(2):86-95. PubMed ID: 3487301
    [No Abstract]   [Full Text] [Related]  

  • 26. Type I interferon and lupus.
    Rönnblom L; Alm GV; Eloranta ML
    Curr Opin Rheumatol; 2009 Sep; 21(5):471-7. PubMed ID: 19525849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis.
    Mor A; Philips MR; Pillinger MH
    Clin Immunol; 2007 Dec; 125(3):215-23. PubMed ID: 17913587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-17 and the Th17 lineage in systemic lupus erythematosus.
    Garrett-Sinha LA; John S; Gaffen SL
    Curr Opin Rheumatol; 2008 Sep; 20(5):519-25. PubMed ID: 18698171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic lupus erythematosus: all roads lead to type I interferons.
    Pascual V; Farkas L; Banchereau J
    Curr Opin Immunol; 2006 Dec; 18(6):676-82. PubMed ID: 17011763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered signal transduction in SLE T cells.
    Tenbrock K; Juang YT; Kyttaris VC; Tsokos GC
    Rheumatology (Oxford); 2007 Oct; 46(10):1525-30. PubMed ID: 17586862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current pathogenetic and immunological aspects of systemic lupus erythematosus. Outline of the problem and personal notes].
    Altucci P; Coraggio F; Catalano G; Farzati B; Astarita C; Fragnito A
    Recenti Prog Med; 1978 Mar; 64(3):275-92. PubMed ID: 351750
    [No Abstract]   [Full Text] [Related]  

  • 32. B cell biology and dysfunction in SLE.
    Anolik JH
    Bull NYU Hosp Jt Dis; 2007; 65(3):182-6. PubMed ID: 17922667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered T and B lymphocyte signaling pathways in lupus.
    Peng SL
    Autoimmun Rev; 2009 Jan; 8(3):179-83. PubMed ID: 18721908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies.
    Sousa E; Isenberg D
    Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):563-74. PubMed ID: 19591785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of lupus therapy modulating autoantigen recognition.
    Okamoto A; Fujio K; Yamamoto K
    Lupus; 2010 Oct; 19(12):1474-81. PubMed ID: 20947560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of levamisole (Decaris) on various immunologic parameters in patients with systemic lupus erythematosus].
    Gandzha IM; Sakharchuk VM; Lysenko GI
    Ter Arkh; 1981; 53(7):121-4. PubMed ID: 6457406
    [No Abstract]   [Full Text] [Related]  

  • 38. Defects in Notch1 upregulation upon activation of T Cells from patients with systemic lupus erythematosus are related to lupus disease activity.
    Sodsai P; Hirankarn N; Avihingsanon Y; Palaga T
    Lupus; 2008 Jul; 17(7):645-53. PubMed ID: 18625637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system.
    Kirou KA; Salmon JE; Crow MK
    Rheum Dis Clin North Am; 2006 Feb; 32(1):103-19, ix. PubMed ID: 16504824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune mechanisms in the pathogenesis of systemic lupus erythematosus.
    Brunner CM; Davis JS
    Bull Rheum Dis; 1975-1976; 26(5-6):854-61. PubMed ID: 764905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.